ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Beijing Biotech, GlaxoSmithKline and AbbVie side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Beijing Biotech×GlaxoSmithKline×AbbVie×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Beijing BiotechGlaxoSmithKlineAbbVie
studies on the registry324,1982,251
open to participants now32135133
phase 3 studies under way07674
reach primary completion within a year316690
programswith a study of their own in two years4085+17 named only70+8 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBeijing BiotechGlaxoSmithKlineAbbVie
Phase 1

Beijing Biotech: 1 of its 40 programs at phase 1

  1. ETB-DualNK-01phase 1
3%

GlaxoSmithKline: 18 of its 85 programs at phase 1

  1. Pn-MAPS30plusphase 1
  2. GSK4771261phase 1
  3. Antibody-drug Conjugate GSK5533524phase 1
  4. ganfeborolephase 1
  5. GSK4425689Aphase 1

and 13 more — sign in to see them all

21%

AbbVie: 28 of its 70 programs at phase 1

  1. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1
  2. surzetoclaxphase 1
  3. BTK Degrader ABBV-101phase 1
  4. ABBV-1162phase 1
  5. ABBV-1451phase 1

and 23 more — sign in to see them all

40%
Phase 2

Beijing Biotech: 39 of its 40 programs at phase 2

  1. Cyclophosphamidephase 2
  2. fludarabinephase 2
  3. Dual-target CAR-NK cellsphase 2
  4. ebnk-1822h2 dual-target cldn18.2phase 2
  5. Lymphodepleting chemotherapyphase 2

and 34 more — sign in to see them all

98%

GlaxoSmithKline: 34 of its 85 programs at phase 2

  1. dezecapavirphase 2
  2. nelistotugphase 2
  3. GSK3862995Bphase 2
  4. VH4524184phase 2
  5. nirogacestatphase 2

and 29 more — sign in to see them all

40%

AbbVie: 20 of its 70 programs at phase 2

  1. ABBV-295phase 2
  2. zumilokibartphase 2
  3. ABBV-932phase 2
  4. trosunilimabphase 2
  5. ABBV-701phase 2

and 15 more — sign in to see them all

29%
Phase 300%

GlaxoSmithKline: 23 of its 85 programs at phase 3

  1. belantamab mafodotinphase 3
  2. felcorekibartphase 3
  3. risvutatug rezetecanphase 3
  4. velzatinibphase 3
  5. efimosfermin alfaphase 3

and 18 more — sign in to see them all

27%

AbbVie: 16 of its 70 programs at phase 3

  1. telisotuzumab adizutecanphase 3
  2. etentamigphase 3
  3. lutikizumabphase 3
  4. mirvetuximab soravtansinephase 3
  5. turmetabart adizutecanphase 3

and 11 more — sign in to see them all

23%
Approved, new studies00%

GlaxoSmithKline: 10 of its 85 programs at approved, new studies

  1. dostarlimabapproved, new study
  2. cabotegravirapproved, new study
  3. depemokimabapproved, new study
  4. belimumabapproved, new study
  5. niraparibapproved, new study

and 5 more — sign in to see them all

12%

AbbVie: 6 of its 70 programs at approved, new studies

  1. upadacitinibapproved, new study
  2. risankizumabapproved, new study
  3. venetoclaxapproved, new study
  4. botulinum toxin type Aapproved, new study
  5. atogepantapproved, new study

and 1 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Beijing Biotech40 readouts · 0 phase 3···

Beijing Biotech, Feb ’27: 11 programs whose next study reaches primary completion

  1. Dual-target CAR-NK cellsphase 2 · Feb 14 · NCT07467863
  2. Dual-target CAR-NK cells (EB-DT-CAR-NK)phase 2 · Feb 14 · NCT07486089
  3. EB-DART-NK01phase 2 · Feb 14 · NCT07744256
  4. EB-DART-NK01 (DLL3/CD56 CAR-NK cells)phase 2 · Feb 14 · NCT07480213
  5. EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)phase 2 · Feb 14 · NCT07480928

and 6 more — sign in to see them all

Beijing Biotech, Mar ’27: 21 programs whose next study reaches primary completion

  1. Autologous Anti-CD19 CAR-expressing T Lymphocytesphase 2 · Mar 14 · NCT07523542
  2. Autologous BCMA/CD19 dual-target CAR-T modulephase 2 · Mar 14 · NCT07523555
  3. Autologous BCMA/CD38 dual-target CAR-T modulephase 2 · Mar 14 · NCT07523555
  4. Autologous BCMA/GPRC5D dual-target CAR-Tphase 2 · Mar 14 · NCT07523555
  5. Autologous CD19/CD20 dual-target CAR-T modulephase 2 · Mar 14 · NCT07523555

and 16 more — sign in to see them all

Beijing Biotech, Apr ’27: 3 programs whose next study reaches primary completion

  1. Autologous dual-target CAR-T cells selected from the predefined target library.phase 2 · Apr 14 · NCT07523529
  2. eb-701phase 2 · Apr 14 · NCT07551349
  3. EB-701/CA9-NKphase 2 · Apr 14 · NCT07551349
·

Beijing Biotech, Jun ’27: 5 programs whose next study reaches primary completion

  1. AP 1903 reagentphase 2 · Jun 14 · NCT07598955
  2. EB-CAR30-NKphase 2 · Jun 14 · NCT07598955
  3. EB-CAR5-NKphase 2 · Jun 14 · NCT07598955
  4. EB-CARMSLN-NKphase 2 · Jun 14 · NCT07598955
  5. EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cellsphase 2 · Jun 14 · NCT07627698
····
GlaxoSmithKline38 readouts · 8 phase 3

GlaxoSmithKline, Nov ’26: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. dostarlimabapproved, new study · Nov 23 · NCT06567782
  2. Pentetic Acidphase 3 · Nov 23 · NCT07596199
  3. niraparibapproved, new study · Nov 26 · NCT03981796

GlaxoSmithKline, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccinephase 1 · Dec 3 · NCT07464314
  2. momelotinibphase 3 · Dec 11 · NCT03441113
  3. GSK3862995Bphase 2 · Dec 16 · NCT06154837
  4. HFA-152aphase 3 · Dec 28 · NCT07645248
  5. norfluranephase 3 · Dec 28 · NCT07645248

and 1 more — sign in to see them all

GlaxoSmithKline, Jan ’27: 4 programs whose next study reaches primary completion

  1. Adjuvanted RSVPreF3 vaccinephase 2 · Jan 12 · NCT07092865
  2. velzatinibphase 3 · Jan 12 · NCT07862114
  3. SOC INSTI-based ARTphase 1 · Jan 22 · NCT07053384
  4. VH3810109phase 2 · Jan 22 · NCT07053384

GlaxoSmithKline, Feb ’27: 2 programs whose next study reaches primary completion

  1. dezecapavirphase 2 · Feb 18 · NCT07934719
  2. Pn-MAPS30plusphase 1 · Feb 22 · NCT07406334

GlaxoSmithKline, Mar ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. depemokimabapproved, new study · Mar 1 · NCT07671001
  2. CAB ULAphase 3 · Mar 8 · NCT06786520
  3. cabotegravirapproved, new study · Mar 8 · NCT06786520
  4. camlipixantphase 3 · Mar 9 · NCT07519395
  5. ozureprubartphase 2 · Mar 16 · NCT07220811

and 1 more — sign in to see them all

GlaxoSmithKline, Apr ’27: 2 programs whose next study reaches primary completion

  1. felcorekibartphase 3 · Apr 13 · NCT07712393
  2. as01ephase 2 · Apr 23 · NCT07036159

GlaxoSmithKline, May ’27: 3 programs whose next study reaches primary completion

  1. VH4770359phase 1 · May 5 · NCT07525544
  2. gepotidacinphase 3 · May 17 · NCT07645235
  3. GSK4771261phase 1 · May 20 · NCT07600450

GlaxoSmithKline, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Bevacizumabphase 2 · Jun 21 · NCT06796907
  2. belimumabapproved, new study · Jun 29 · NCT06411249
  3. Low dose Strep A Alumphase 1 · Jun 29 · NCT07085702
  4. Low dose Strep A AS37phase 1 · Jun 29 · NCT07085702

GlaxoSmithKline, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mRNA Seasonal Flu vaccinephase 3 · Jul 9 · NCT07851246

GlaxoSmithKline, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. belantamabphase 2 · Aug 5 · NCT07742527
  2. shingrixapproved, new study · Aug 23 · NCT05371080

GlaxoSmithKline, Sep ’27: 1 program whose next study reaches primary completion

  1. mocertatug rezetecanphase 3 · Sep 22 · NCT06431594

GlaxoSmithKline, Oct ’27: 4 programs whose next study reaches primary completion

  1. GSK3772701phase 2 · Oct 8 · NCT07545681
  2. efimosfermin alfaphase 3 · Oct 13 · NCT07358546
  3. Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514phase 2 · Oct 26 · NCT06990880
  4. VH4524184phase 2 · Oct 28 · NCT07202546
AbbVie34 readouts · 5 phase 3

AbbVie, Nov ’26: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-701phase 2 · Nov 0 · NCT06895343
  2. ABBV-932phase 2 · Nov 0 · NCT06846320
  3. mirvetuximab soravtansinephase 3 · Nov 0 · NCT05456685
  4. upadacitinibapproved, new study · Nov 0 · NCT06389136
  5. venetoclaxapproved, new study · Nov 0 · NCT04895436

and 1 more — sign in to see them all

AbbVie, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-295phase 2 · Dec 0 · NCT07514260
  2. emraclidinephase 2 · Dec 0 · NCT07219030
  3. lutikizumabphase 3 · Dec 0 · NCT06468228
  4. telisotuzumab adizutecanphase 3 · Dec 0 · NCT06107413

AbbVie, Jan ’27: 1 program whose next study reaches primary completion

  1. risankizumabapproved, new study · Jan 0 · NCT07466550

AbbVie, Feb ’27: 9 programs whose next study reaches primary completion

  1. [11C]ABBV-112iearly phase 1 · Feb 0 · NCT07933497
  2. ABBV-859phase 1 · Feb 0 · NCT07736638
  3. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1 · Feb 0 · NCT05512390
  4. etentamigphase 3 · Feb 0 · NCT06223516
  5. MEDI0618phase 2 · Feb 0 · NCT06602479

and 4 more — sign in to see them all

·

AbbVie, Apr ’27: 1 program whose next study reaches primary completion

  1. ABBV-1451phase 1 · Apr 0 · NCT07570147

AbbVie, May ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-1162phase 1 · May 0 · NCT07832708
  2. ABBV-243phase 1 · May 0 · NCT07306754
  3. ABBV-7828phase 1 · May 0 · NCT07856706
  4. Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969phase 1 · May 0 · NCT06318273
  5. trosunilimabphase 2 · May 0 · NCT07925983

and 1 more — sign in to see them all

AbbVie, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. botulinum toxin type Aapproved, new study · Jun 0 · NCT07794891

AbbVie, Jul ’27: 4 programs whose next study reaches primary completion

  1. ABBV-1606phase 1 · Jul 0 · NCT07935564
  2. azirkitugphase 1 · Jul 0 · NCT05005403
  3. surzetoclaxphase 2 · Jul 0 · NCT06291220
  4. surzetoclaxphase 1 · Jul 0 · NCT06291220

AbbVie, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. vedolizumabphase 3 · Aug 0 · NCT06880744

AbbVie, Sep ’27: 1 program whose next study reaches primary completion

  1. icalcaprantphase 2 · Sep 0 · NCT07276997
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 24, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Beijing Biotech

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

GlaxoSmithKline

New programs 4

Reached a new phase 0

None

Study stopped 2

  • camlipixantphase 3 · terminated Nov 20“The study has been terminated due to the decision to cease further development of camlipixant in refractory…” · NCT05600777
  • camlipixantphase 3 · terminated Nov 20“The study has been withdrawn terminated due to the decision to cease further development of camlipixant in …” · NCT07650084

Primary completion later 10

AbbVie

New programs 5

Reached a new phase 1

  • ABBV-722phase 3 · Oct 23 · Scleroderma, Systemic

Study stopped 0

None

Primary completion later 10

Where they overlap

Conditions where at least two of them have programs: 35 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionBeijing BiotechGlaxoSmithKlineAbbVie
Carcinoma, Non-Small-Cell Lungall three · compare here

Beijing Biotech in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. Cyclophosphamidephase 2
  2. Dual-target CAR-NK cellsphase 2

Their studies: Beijing Biotech’s studies of Carcinoma, Non-Small-Cell Lung in search

GlaxoSmithKline in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. risvutatug rezetecanphase 3
  2. momelotinibphase 3
  3. neladalkibphase 3
  4. feladilimabphase 3
  5. nelistotugphase 2

and 3 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Carcinoma, Non-Small-Cell Lung in search

AbbVie in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. telisotuzumab adizutecanphase 3
  2. ABBV-1480phase 3
  3. azirkitugphase 1
  4. RC148no phase

Their studies: AbbVie’s studies of Carcinoma, Non-Small-Cell Lung in search

Neoplasmsall three · compare here

Beijing Biotech in Neoplasms: 4 programs

  1. Lymphodepleting chemotherapyphase 2
  2. Cytokine supportphase 2
  3. EB-PT-CAR-NK-Dphase 2
  4. EB-PT-CAR-NK-Sphase 2

Their studies: Beijing Biotech’s studies of Neoplasms in search

Multiple Myelomaall three · compare here

Beijing Biotech in Multiple Myeloma: 2 programs

  1. Cyclophosphamidephase 2
  2. fludarabinephase 2

Their studies: Beijing Biotech’s studies of Multiple Myeloma in search

GlaxoSmithKline in Multiple Myeloma: 5 programs

  1. belantamab mafodotinphase 3
  2. feladilimabphase 3
  3. nirogacestatphase 2
  4. belantamabphase 2
  5. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Multiple Myeloma in search

Colorectal Neoplasmsall three · compare here

Beijing Biotech in Colorectal Neoplasms: 1 program

  1. EB-DUO-CAR-NK-CEA/GCCphase 2

Their studies: Beijing Biotech’s studies of Colorectal Neoplasms in search

AbbVie in Colorectal Neoplasms: 3 programs

  1. telisotuzumab adizutecanphase 3
  2. trifluridine tipiracil drug combinationphase 3
  3. RC148no phase

Their studies: AbbVie’s studies of Colorectal Neoplasms in search

Prostatic Neoplasmsall three · compare here

Beijing Biotech in Prostatic Neoplasms: 2 programs

  1. AP 1903 reagentphase 2
  2. ETB-DualNK-01phase 1

Their studies: Beijing Biotech’s studies of Prostatic Neoplasms in search

Small Cell Lung Carcinomaall three · compare here

GlaxoSmithKline in Small Cell Lung Carcinoma: 2 programs

  1. risvutatug rezetecanphase 3
  2. ivonescimabphase 2

Their studies: GlaxoSmithKline’s studies of Small Cell Lung Carcinoma in search

Breast Neoplasmsall three · compare here

Beijing Biotech in Breast Neoplasms: 1 program

  1. Cyclophosphamidephase 2

Their studies: Beijing Biotech’s studies of Breast Neoplasms in search

GlaxoSmithKline in Breast Neoplasms: 3 programs

  1. nirogacestatphase 2
  2. Bevacizumabphase 2
  3. niraparibapproved, new study

Their studies: GlaxoSmithKline’s studies of Breast Neoplasms in search

AbbVie in Breast Neoplasms: 2 programs

  1. trifluridine tipiracil drug combinationphase 3
  2. RC148no phase

Their studies: AbbVie’s studies of Breast Neoplasms in search

Squamous Cell Carcinoma of Head and Neckall three · compare here

Beijing Biotech in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. EGFR/HER2 Dual-Target CAR-NK Cellsphase 2

Their studies: Beijing Biotech’s studies of Squamous Cell Carcinoma of Head and Neck in search

GlaxoSmithKline in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. feladilimabphase 3
  2. nelistotugphase 2

Their studies: GlaxoSmithKline’s studies of Squamous Cell Carcinoma of Head and Neck in search

AbbVie in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. telisotuzumab adizutecanphase 3
  2. ABBV-711phase 1

Their studies: AbbVie’s studies of Squamous Cell Carcinoma of Head and Neck in search

Lymphoma, Non-Hodgkinall three · compare here

Beijing Biotech in Lymphoma, Non-Hodgkin: 1 program

  1. fludarabinephase 2

Their studies: Beijing Biotech’s studies of Lymphoma, Non-Hodgkin in search

GlaxoSmithKline in Lymphoma, Non-Hodgkin: 1 program

  1. GSK5926371phase 2

Their studies: GlaxoSmithKline’s studies of Lymphoma, Non-Hodgkin in search

AbbVie in Lymphoma, Non-Hodgkin: 1 program

  1. venetoclaxapproved, new study

Their studies: AbbVie’s studies of Lymphoma, Non-Hodgkin in search

Ovarian Neoplasms2 of 3 · compare here–

GlaxoSmithKline in Ovarian Neoplasms: 6 programs

  1. mocertatug rezetecanphase 3
  2. nirogacestatphase 2
  3. Bevacizumabphase 2
  4. ivonescimabphase 2
  5. dostarlimabapproved, new study

and 1 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Ovarian Neoplasms in search

Arthritis, Rheumatoid2 of 3 · compare here–

GlaxoSmithKline in Arthritis, Rheumatoid: 1 program

  1. belimumabapproved, new study

Their studies: GlaxoSmithKline’s studies of Arthritis, Rheumatoid in search

AbbVie in Arthritis, Rheumatoid: 5 programs

  1. lutikizumabphase 3
  2. ABBV-722phase 3
  3. ravagalimabphase 2
  4. CPTX2309phase 1
  5. upadacitinibapproved, new study

Their studies: AbbVie’s studies of Arthritis, Rheumatoid in search

Asthma2 of 3 · compare here–

GlaxoSmithKline in Asthma: 5 programs

  1. felcorekibartphase 3
  2. norfluranephase 3
  3. HFA-152aphase 3
  4. ozureprubartphase 2
  5. depemokimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Asthma in search

AbbVie in Asthma: 1 program

  1. zumilokibartphase 2

Their studies: AbbVie’s studies of Asthma in search

Show all 35

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Beijing Biotech 1 of 40 · GlaxoSmithKline 63 of 85 · AbbVie 54 of 70 programs (30 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (GlaxoSmithKline: 17, AbbVie: 8).